A Phase 4 interventional study of Ranibizumab in Visual Impairment and Macular Edema, sponsored by Novartis Pharmaceuticals. Completed at 43 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-02-23.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing ranibizumab in Vision Disorders — none open to participants now, none under way, none of them phase 3. Ranibizumab · Vision Disorders.
Among the 26 studies testing ranibizumab in Vision Disorders, this one is the 2nd largest by enrollment, is one of 4 that started in 2011, is one of 7 in phase 4, and was the 7th registered.
361 studies on the registry are indexed under Vision Disorders; 85 are open to participants now.
Browse Vision Disorders studies →None of the 26 studies testing ranibizumab in Vision Disorders is open now. The open studies under Vision Disorders, anywhere →
Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 46 Vision Disorders studies recruiting now, 21 (46%) set no upper age limit and 16 (35%) stop at 75 or younger; 18 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 4 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 394 is above the median of 75 across 245 interventional studies indexed under Vision Disorders.
Median enrollment 178 across the 26 interventional studies. Of the 22 that completed or were terminated, 19 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 26 have an industry lead sponsor. The 6 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
32 studies in Vision Disorders by Novartis: none open now, none under way, none of them phase 3. Of 30 finished, 25 (83%) have results posted.
Among the 32 studies in Vision Disorders by Novartis, this one is the 6th largest by enrollment of the 31 interventional ones that give a count, is one of 5 that started in 2011, is one of 11 in phase 4, and was the 4th registered.
Novartis’s Vision Disorders studies by the year they started, since 2009.
None of the studies under way reaches primary completion within a year.
Among the 26 studies testing ranibizumab in Vision Disorders, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 32 in Vision Disorders:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the proportion of patients with a 10 letters gain on Best Corrected Visual Acuity (BCVA) at 6 months in current medical practice.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Ocular concomitant conditions/ diseases
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Ranibizumab
proportion of patients with a 10 letters gain on Best Corrected Visual Acuity (BCVA)
Time frame: 6 months
mean average change in BCVA from baseline
Time frame: 6 months
if the letters gain after 2 injections is predictive from the letters gain at 6 months
Time frame: 6 months
mean number of injections needed to obtain a 10 letters gain
Time frame: 6 months
mean number of injections needed to obtain a stable visual acuity for three consecutive monthly assessments
Time frame: 6 months
efficacy of ranibizumab IVT on Central Retinal Thickness (OCT)
Time frame: 6 months
The record gives a start of Feb 2011, a primary completion of Aug 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranibizumab